Dose-ranging study of riluzole in amyotrophic lateral sclerosis
The LancetPublished 1 May 1996
Lucette Lacomblez, Gilbert Bensimon, Vincent Meininger, P. Nigel Leigh, Philippe Guillet, P Guillet
Citations1,281
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A double-blind, placebo-controlled, multicentre study to confirm that riluzole is well tolerated and lengthens survival of patients with ALS, and suggests that the 100 mg dose of rILuzole has the best benefit-to-risk ratio.
Abstract
Overall, efficacy and safety results suggest that the 100 mg dose of riluzole has the best benefit-to-risk ratio. This study confirms that riluzole is well tolerated and lengthens survival of patients with ALS.
Keywords
ChemistryMedicine
New England Journal of MedicineA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
2,157 Citations1994Gilbert Bensimon, Lucette Lacomblez +1 more
The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.
Journal of the American Statistical AssociationThe Design and Analysis of Sequential Clinical Trials.
638 Citations1985David Harrington, John Whitehead
Estimation and Comparison of Changes in the Presence of Information Right Censoring by Modeling the Censoring Process.
531 Citations1987Margaret Wu, Raymond J. Carroll
Clinical EpidemiologyRisk factors for amyotrophic lateral sclerosis
443 Citations2015Fang Fang, Caroline Ingre +3 more
FEBS LettersExpression cloning of an epithelial amiloride‐sensitive Na<sup>+</sup> channel
345 Citations1993Éric Lingueglia, Nicolas Voilley +3 more
A complementary DNA encoding an amiloride‐sensitive Na+ channel has been cloned and characterized from rat colon and homologies have been found between a part of the channel sequence and the Mec4 gene product of Caenorhabditis elegans, a protein associated with mutation‐induced neuronal degeneration.
Journal of the Neurological SciencesOnset, natural history and outcome in idiopathic adult motor neuron disease
301 Citations1993Forbes H. Norris, Rodger Shepherd +6 more
Among 708 cases aged 25-74 years at onset, the most common type was typical, sporadic amyotrophic lateral sclerosis (SporALS), and Familial ALS (FamALS) was diagnosed in 7%.
European Journal of PharmacologyThe neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1
256 Citations1993David Martin, Michael A. Thompson +1 more
It is demonstrated that 10-30 microM riluzole reduces the K(+)-evoked release of glutamate and aspartate from slices of hippocampal area CA1, and higher concentrations reduced gamma-aminobutyrate release.
European Journal of PharmacologyInhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes
210 Citations1993Marc-Williams Debono, Joëlle Le Guern +3 more
A direct but non-competitive action of riluzole on ionotropic glutamate receptors is suggested, similar to that of the channel blocker MK-801.
Molecular PharmacologyBlock of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole.
188 Citations1994Terence E. Hébert, Pierre Drapeau +2 more
The results show that the riluzole binding site is on the alpha subunit of the sodium channel, and they suggest that stabilization of the inactivated state may underlie the neuroprotective properties of rilzole.
BiometricsThe Design and Analysis of Sequential Clinical Trials.
182 Citations1983R. J. Prescott, John Whitehead
PubMedExcitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
177 Citations1995Rothstein Jd
Experimental paradigms suggest that, even if secondary, glutamate could contribute to the death of motor neurons, and interventions to minimize the toxicity of glutamate (e.g., receptor antagonists, release inhibitors, or antioxidants) could partially ameliorate the degeneration of motor neuron.
British Journal of PharmacologyAntagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action
129 Citations1994Jean‐Pierre Hubert, Jean-Christophe Delumeau +3 more
It is concluded that riluzole has a dual action on cerebellar granule cells, both blocking voltage‐dependent sodium channels and interfering with NMDA receptor‐mediated responses via a pertussis toxin‐sensitive mechanism.
Muscle & NerveDuration of amyotrophic lateral sclerosis is age dependent
129 Citations1993Andrew Eisen, Michael Schulzer +3 more
It is concluded that onset age, but no sex, is the most significant predictor determining disesae duration in ALS, and longer survival in younger patients probably reflects their greater neuronal reserve.
Brain Research ReviewsAmino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders
117 Citations1993Brian S. Meldrum
The possibility that some acidic amino acids occurring naturally or as additives in the diet can act as excitotoxins producing central nervous system pathology has been the subject of extensive debate in the last 20 years and is reviewed.
Muscle & NerveSurvival prediction in amyotrophic lateral sclerosis
101 Citations1989Charles K. Jablecki, Charles C. Berry +1 more
This longitudinal study of 194 patients with sporadic ALS demonstrated that it is possible for physicians to predict the approximate survival time for an individual ALS patient given: the age of the patient, the duration of his weakness and an estimate of his clinical disability (ALS Score).
Journal of the Neurological SciencesExcitotoxicity and motor neurone disease: A review of the evidence
94 Citations1994Pamela J. Shaw
The evidence, while still circumstantial, is sufficient to warrant further research effort in this field, not least because the emergence of pharmacological agents which modify specific aspects of excitatory amino acid neurotransmission offer the possibility of therapeutic intervention in MND.
Neuroscience LettersPertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on d[3H]aspartate release from cultured cerebellar granule cells
79 Citations1992Adam Doble, Jean‐Pierre Hubert +1 more
Neuroscience LettersNeuroprotective effects of riluzole on or veratridine-induced neurotoxicity in rat hippocampal slices
70 Citations1994C. Malgouris, Marc Daniel +1 more
The view that the neuroprotective properties of riluzole could be exerted via two distinct mechanisms of action is supported.
NeuroreportNeuroprotective effects of riluzole in ALS CSF toxicity
67 Citations1994Philippe Couratier, Philippe Sindou +3 more
Riluzole (5 x 10(-7) M) which reduces excitatory amino acid release, could represent a new pharmacological agent susceptible to be proposed to patients affected by this dramatic neurological disease.
NeuroepidemiologyPrognostic Factors and Survival in Amyotrophic Lateral Sclerosis
67 Citations1994Ole-Bjørn Tysnes, Stein Emil Vollset +2 more
NeuroepidemiologyClinical Statistics in 515 Fatal Cases of Motor Neuron Disease
22 Citations1985Kiyotaro Kondo, Isao Hemmi